Disc Medicine IRON Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Bitopertin | $59.73M+98.0% | $58.83M+109% | $51.32M+105% | $46.75M+111% | $30.17M+56.1% | |
| DISC Three Four Zero Five | $25.21M+131% | $17.69M+27.0% | $17.6M+4.3% | $8.94M-52.1% | $10.9M-45.0% | |
| DISC Zero Nine Seven Four | $29.57M+53.3% | $27.59M+62.8% | $22.32M+48.6% | $20.62M+77.3% | $19.29M+81.6% | |
| Internal Research And Development | $41.51M+65.2% | $36.95M+55.4% | $33.6M+61.4% | $28.48M+47.8% | $25.13M+43.4% | |
| Other Research | $13.93M+99.3% | $13.6M+97.7% | $11.02M+81.2% | $8.16M+35.2% | $6.99M+32.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Disc Medicine break its business down?
- Disc Medicine (IRON) reports research and development expense by product across 5 parts — Bitopertin, DISC Three Four Zero Five, DISC Zero Nine Seven Four, Internal Research And Development and Other Research. Each is extracted from the segment footnotes and tracked over time.
- Where does Disc Medicine's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Disc Medicine's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.